Abstract:Background: Although the first generation of proteasome inhibitor bortezomib is very effective, the development of resistance limits it long-term utility. In this study, we explored the efficiency and molecular mechanisms of the novel, irreversible proteasome inhibitor BSc2118, particularly, the reversal of bortezomib resistance. Materials and Methods: Human MM cell lines (MM.1S, MM.1R, RPMI-8226, U266, NCI-H929) were treated with BSc2118 at various concentrations for 48h, and assessment for cell viability by CCK-8 assay. MM.1S and MM.1R cells were treated with BSc2118 for 24 hours, and cell cycle and apoptosis analysis were conducted by flow cytometry. Associated molecules were detected by qRT-PCR and western blot. Chymotrypsin-like proteasome activity assay was performed by using the 20S proteasome assay kit. Ubiquitinated proteins were isolated and determined with ubiquitin enrichment kit. Results: Our results revealed that treatment of MM cell lines with BSc2118 inhibits the chymotrypsin-like proteasome activity and induces accumulation of ubiquitinated proteins. BSc2118 inhibits MM cell growth and induces MM apoptosis via induction of G2/M phase arrest, activation of cleaved caspase-3, caspase-8 and caspase-9 and PARP, increasing p53, p21 and E2F1, and inhibition of autophagy in MM.1S, MM.1R and RPMI-8226 cell lines. In addition, BSc2118 dramatically inhibits cytokines mRNA, such as IL-6, VEGF and bFGF in both myeloma cells line and primary bone marrow stromal cells from myeloma patients. More importantly, BSc2118 could overcome bortezomib resistance in vitro by using primary CD138 positive plasma cells from bortezomib-resistant myeloma patients and bortezomib resistance cell line ANBL-6 (ANBL-6.BR), most likely as the consequence of inhibition of autophagy flux which is responsible for bortezomib resistance. Conclusion: Our study revealed BSc2118, a novel irreversible proteasome inhibitor, exerts anti-MM effect, mainly through activation of caspase pathway and inhibition of basal autophagy. It is of great importance that BSc2118 could overcome bortezomib resistance via inhibition of autophagy flux. A head to head of BSc2118 versus Bortezomib is performing in human plasmacytoma xenograft tumor model to evaluate drug safety, anti-tumor efficiency, in particular, reversal of bortezomib resistance. Our preclinical study supports clinical evaluation of BSc2118, particularly, overcomes bortezomib resistance, as a potential MM therapy. Disclosures No relevant conflicts of interest to declare.

Synthesis of a Bone-Targeted Bortezomib with in Vivo Anti-Myeloma Effects in Mice

Bone-Targeted Bortezomib Inhibits Bortezomib-Resistant Multiple Myeloma in Mice by Providing Higher Levels of Bortezomib in Bone

Targeting Bortezomib to Bone Increases Its Bone Anabolic Activity and Reduces Systemic Adverse Effects in Mice

Biomimetic Platelet Nanoparticles Encapsulated with Proteasome Inhibitor Bortezomib for Multiple Myeloma Treatment

Hyaluronic Acid Shell and Disulfide-Crosslinked Core Micelles for in Vivo Targeted Delivery of Bortezomib for the Treatment of Multiple Myeloma.

Bortezomib Potentiates Antitumor Activity of Mitoxantrone Through Dampening Wnt/β-catenin Signal Pathway in Prostate Cancer Cells

Enhanced Precision Therapy of Multiple Myeloma Through Engineered Biomimetic Nanoparticles with Dual Targeting

Anti-BCMA-engineered Exosomes for Bortezomib Targeted Delivery in Multiple Myeloma

Bortezomib Rescues Ovariectomy-Induced Bone Loss via SMURF-Mediated Ubiquitination Pathway

Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models

Engineered Nanomedicine for Myeloma and Bone Microenvironment Targeting.

A Targeted and pH-Responsive Bortezomib Nanomedicine in the Treatment of Metastatic Bone Tumors

Antitumor Activity of a Novel Proteasome Inhibitor BSc2118 Against Multiple Myeloma

Anti-β2 Microglobulin Monoclonal Antibodies Overcome Bortezomib-Induced Drug Resistance in Multiple Myeloma by Inhibition of Autophagy

Anti-tumor Activity of the Proteasome Inhibitor BSc2118 Against Human Multiple Myeloma.

Anti-BCMA surface engineered biomimetic photothermal nanomissile enhances multiple myeloma cell apoptosis and overcomes the disturbance of NF-KB signaling<i> in</i><i> vivo</i>

A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib

Bortezomib-catechol Conjugated Prodrug Micelles: Combining Bone Targeting and Aryl Boronate-Based Ph-Responsive Drug Release for Cancer Bone-Metastasis Therapy

Small Molecule Bda-366 As a Bcl2-BH4 Antagonist for Multiple Myeloma Therapy

A novel phosphoramide compound, DCZ0847, displays <i>in vitro</i> and <i>in vivo</i> anti-myeloma activity, alone or in combination with bortezomib

Quantitative Phosphoproteomics Of Proteasome Inhibition In Multiple Myeloma Cells